文献速递甲状腺核医学核素与放射性配体治疗肿瘤 PET/CT

[68Ga]Ga-DOTA-FAPI-04 PET/CT检测甲状腺髓样癌复发及靶向核素治疗筛选

Clinical performance of [68Ga]Ga-DOTA-FAPI-04 PET/CT in detecting recurrent disease in medullary thyroid carcinoma: a comparative analysis with [18F]F-FDG and [68Ga]Ga-DOTATATE PET/CT, alongside identification of suitable candidates for targeted radionuclide therapy.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-07-01

这项前瞻性单中心研究纳入56例疑似复发性甲状腺髓样癌(MTC)患者,比较[68Ga]Ga-DOTA-FAPI-04、[18F]F-FDG与[68Ga]Ga-DOTATATE PET/CT的诊断效能。FAPI-04在患者层面的灵敏度和准确率高于FDG与DOTATATE,并改变35.7%患者的临床管理;探索性FAST评分用于分层选择放射性药物治疗。

要点

  • FAPI-04患者层面灵敏度95.92%、准确率94.64%,高于FDG与DOTATATE。
  • FAPI-04对纵隔淋巴结、肝和骨骼转移灶有较高检出率。
  • 探索性FAST评分可分层指导[177Lu]Lu-FAPI-RPT等个体化治疗。

核心结论

  • [68Ga]Ga-DOTA-FAPI-04 PET/CT对复发性MTC的诊断准确率高于[18F]F-FDG和[68Ga]Ga-DOTATATE PET/CT。
  • 探索性FAST评分提供患者分层框架,但需更大规模多中心试验验证后方可用于临床。

研究设计与样本

  • 前瞻性单中心研究,纳入56例疑似复发性MTC患者,均接受[68Ga]Ga-DOTA-FAPI-04、[18F]F-FDG和[68Ga]Ga-DOTATATE PET/CT检查。
  • 主要终点为患者层面复发诊断准确率;次要终点包括按预设解剖区域的病灶检出率、与生化及临床病理参数的相关性、无进展生存预后评估,并开发FAST评分指导个体化放射性药物治疗。

主要发现

  • 患者层面分析中,[68Ga]Ga-DOTA-FAPI-04灵敏度95.92%、准确率94.64%,[18F]F-FDG为89.80%和89.29%,[68Ga]Ga-DOTATATE为77.55%和76.79%。
  • [68Ga]Ga-DOTA-FAPI-04对纵隔淋巴结(91.9%)、肝(91.7%)和骨骼(86.5%)转移灶检出率较高。
  • [68Ga]Ga-DOTA-FAPI-04摄取与较短的平均无进展生存相关,并使35.7%患者临床管理发生改变。

关键数值与推荐

  • FAST评分将34例(60.7%)分层为[177Lu]Lu-FAPI-RPT,8例(14.3%)为[177Lu]Lu-DOTATATE PRRT,9例(16.1%)为任一或联合RPT。

临床怎么用

  • 对疑似复发性MTC,可考虑[68Ga]Ga-DOTA-FAPI-04 PET/CT以提高复发灶检出并影响临床决策。
  • FAST评分目前仅作为探索性分层工具,尚不能常规用于放射性药物治疗选择。

局限性

  • FAST评分需未来通过更大规模多中心试验验证后方可临床采用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: To evaluate and compare the diagnostic performance of [68Ga]Ga-DOTA-FAPI-04 with [18F]F-FDG and [68Ga]Ga-DOTATATE PET/CT for detecting recurrent disease in patients with medullary thyroid carcinoma (MTC) and additionally evaluate their role for prognostication and theranostics in management of MTC. METHODS: In this prospective single-centre study, 56 patients with suspected recurrent MTC underwent [68Ga]Ga-DOTA-Fibroblast activation protein inhibitor (FAPI)-04, [18F]F-FDG, and [68Ga]Ga-DOTATATE PET/CT. The primary endpoint was patient-based diagnostic accuracy for recurrent disease. Secondary endpoints included lesion-based detection rates across pre-defined anatomical regions, correlation with biochemical and clinicopathological parameters, prognostic assessment for progression-free survival, and a novel exploratory FAPI-SSTR Theranostic (FAST) score was developed to guide personalized radiopharmaceutical therapy (RPT). RESULTS: [68Ga]Ga-DOTA-FAPI-04 PET/CT demonstrated higher sensitivity 95.92% and accuracy 94.64% compared to [18F]F-FDG-PET/CT (sensitivity: 89.80%, accuracy: 89.29%) and [68Ga]Ga-DOTATATE (sensitivity: 77.55%, accuracy: 76.79%) on patient-based analysis for detecting recurrent disease. [68Ga]Ga-DOTA-FAPI-04 was showed high detection rates for disease recurrence in mediastinal nodal (91.9%), liver (91.7%), and skeletal (86.5%) metastases.[68Ga]Ga-DOTA-FAPI-04 uptake was associated with a modestly shorter mean progression-free survival and altered clinical management in 35.7% of total patients. Additionally, the pre-defined exploratory FAST scoring system stratified 34 patients (60.7%) for [177Lu]Lu-FAPI-RPT, 8 (14.3%) for [177Lu]Lu-DOTATATE PRRT, and 9 (16.1%) for either or combined RPT. CONCLUSION: [68Ga]Ga-DOTA-FAPI-04 PET/CT showed higher diagnostic accuracy for the identification of recurrent MTC over standard [18F]F-FDG and [68Ga]Ga-DOTATATE PET/CT, with higher regional detection rates for liver and osteoblastic skeletal metastases. Furthermore, while the exploratory FAST score provides a framework for patient stratification and personalizing targeted theranostic strategies, it requires future validation through larger multicentre trials prior to clinical adoption.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Ravada SK, Parghane RV, Deshmukh A, et al. Clinical performance of [68Ga]Ga-DOTA-FAPI-04 PET/CT in detecting recurrent disease in medullary thyroid carcinoma: a comparative analysis with [18F]F-FDG and [68Ga]Ga-DOTATATE PET/CT, alongside identification of suitable candidates for targeted radionuclide therapy. Eur J Nucl Med Mol Imaging. 2026. PMID: 42384206. doi:10.1007/s00259-026-08031-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。